Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
3.940
+0.040 (1.03%)
Sep 2, 2026, 4:00 PM EDT - Market closed

Protara Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
23.5621.9217.4518.6220.7426.4
Research & Development
53.2342.6331.724.9916.8121.09
Operating Expenses
76.7964.5549.1543.6137.5547.49
Operating Income
-76.79-64.55-49.15-43.61-37.55-47.49
Interest & Investment Income
6.536.384.173.191.110.24
Other Non Operating Income (Expenses)
0.250.730.39---
EBT Excluding Unusual Items
-70.02-57.44-44.6-40.42-36.44-47.25
Impairment of Goodwill
-----29.52-
Pretax Income
-70.02-57.44-44.6-40.42-65.95-47.25
Net Income
-70.02-57.44-44.6-40.42-65.95-47.25
Net Income to Common
-70.02-57.44-44.6-40.42-65.95-47.25
Net Income Growth
------
Shares Outstanding (Basic)
524321111111
Shares Outstanding (Diluted)
524321111111
Shares Change
55.93%108.02%81.73%0.64%0.24%55.28%
EPS (Basic)
-1.35-1.34-2.17-3.57-5.86-4.21
EPS (Diluted)
-1.35-1.34-2.17-3.57-5.86-4.21
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-66.49-56.46-35.87-37.6-26.58-35.1
Free Cash Flow Per Share
-1.28-1.32-1.74-3.32-2.36-3.13
EBITDA
-76.45-64.19-48.82-43.27-37.3-47.37
D&A For EBITDA
0.340.360.330.340.250.12
EBIT
-76.79-64.55-49.15-43.61-37.55-47.49
SEC Filings: 10-K · 10-Q